1. Home
  2. CNTX vs IOR Comparison

CNTX vs IOR Comparison

Compare CNTX & IOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTX
  • IOR
  • Stock Information
  • Founded
  • CNTX 2015
  • IOR 1984
  • Country
  • CNTX United States
  • IOR United States
  • Employees
  • CNTX N/A
  • IOR N/A
  • Industry
  • CNTX Biotechnology: Pharmaceutical Preparations
  • IOR Real Estate Investment Trusts
  • Sector
  • CNTX Health Care
  • IOR Real Estate
  • Exchange
  • CNTX Nasdaq
  • IOR Nasdaq
  • Market Cap
  • CNTX 75.6M
  • IOR 72.8M
  • IPO Year
  • CNTX 2021
  • IOR N/A
  • Fundamental
  • Price
  • CNTX $0.82
  • IOR $18.20
  • Analyst Decision
  • CNTX Strong Buy
  • IOR
  • Analyst Count
  • CNTX 5
  • IOR 0
  • Target Price
  • CNTX $5.25
  • IOR N/A
  • AVG Volume (30 Days)
  • CNTX 162.2K
  • IOR 175.0
  • Earning Date
  • CNTX 11-05-2025
  • IOR 11-06-2025
  • Dividend Yield
  • CNTX N/A
  • IOR N/A
  • EPS Growth
  • CNTX N/A
  • IOR N/A
  • EPS
  • CNTX N/A
  • IOR 1.06
  • Revenue
  • CNTX N/A
  • IOR N/A
  • Revenue This Year
  • CNTX N/A
  • IOR N/A
  • Revenue Next Year
  • CNTX N/A
  • IOR N/A
  • P/E Ratio
  • CNTX N/A
  • IOR $17.24
  • Revenue Growth
  • CNTX N/A
  • IOR N/A
  • 52 Week Low
  • CNTX $0.49
  • IOR $16.01
  • 52 Week High
  • CNTX $2.59
  • IOR $19.69
  • Technical
  • Relative Strength Index (RSI)
  • CNTX 52.03
  • IOR 33.70
  • Support Level
  • CNTX $0.81
  • IOR $18.01
  • Resistance Level
  • CNTX $0.94
  • IOR $18.89
  • Average True Range (ATR)
  • CNTX 0.05
  • IOR 0.02
  • MACD
  • CNTX -0.01
  • IOR -0.01
  • Stochastic Oscillator
  • CNTX 10.36
  • IOR 28.36

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

About IOR Income Opportunity Realty Investors Inc.

Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. The business of the company is managed by Pillar Income Asset Management, Inc. The company's activities include locating, evaluating and recommending investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.

Share on Social Networks: